These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

473 related items for PubMed ID: 18370574

  • 1. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial.
    Chang JS, Ahn YM, Park HJ, Lee KY, Kim SH, Kang UG, Kim YS.
    J Clin Psychiatry; 2008 May; 69(5):720-31. PubMed ID: 18370574
    [Abstract] [Full Text] [Related]

  • 2. Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care: a randomized, controlled trial.
    Barbui C, Accordini S, Nosè M, Stroup S, Purgato M, Girlanda F, Esposito E, Veronese A, Tansella M, Cipriani A, CHAT (Clozapine Haloperidol Aripiprazole Trial) Study Group.
    J Clin Psychopharmacol; 2011 Jun; 31(3):266-73. PubMed ID: 21508849
    [Abstract] [Full Text] [Related]

  • 3. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia.
    Findling RL, Robb A, Nyilas M, Forbes RA, Jin N, Ivanova S, Marcus R, McQuade RD, Iwamoto T, Carson WH.
    Am J Psychiatry; 2008 Nov; 165(11):1432-41. PubMed ID: 18765484
    [Abstract] [Full Text] [Related]

  • 4. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy.
    Kane JM, Correll CU, Goff DC, Kirkpatrick B, Marder SR, Vester-Blokland E, Sun W, Carson WH, Pikalov A, Assunção-Talbott S.
    J Clin Psychiatry; 2009 Oct; 70(10):1348-57. PubMed ID: 19906340
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.
    Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW.
    J Clin Psychiatry; 2002 Sep; 63(9):763-71. PubMed ID: 12363115
    [Abstract] [Full Text] [Related]

  • 6. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.
    de Lucena D, Fernandes BS, Berk M, Dodd S, Medeiros DW, Pedrini M, Kunz M, Gomes FA, Giglio LF, Lobato MI, Belmonte-de-Abreu PS, Gama CS.
    J Clin Psychiatry; 2009 Oct; 70(10):1416-23. PubMed ID: 19906345
    [Abstract] [Full Text] [Related]

  • 7. Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study.
    Muscatello MR, Bruno A, Pandolfo G, Micò U, Scimeca G, Di Nardo F, Santoro V, Spina E, Zoccali RA.
    Schizophr Res; 2011 Apr; 127(1-3):93-9. PubMed ID: 21262565
    [Abstract] [Full Text] [Related]

  • 8. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial.
    Fleischhacker WW, Heikkinen ME, Olié JP, Landsberg W, Dewaele P, McQuade RD, Loze JY, Hennicken D, Kerselaers W.
    Int J Neuropsychopharmacol; 2010 Sep; 13(8):1115-25. PubMed ID: 20459883
    [Abstract] [Full Text] [Related]

  • 9. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine.
    Kane JM, Meltzer HY, Carson WH, McQuade RD, Marcus RN, Sanchez R, Aripiprazole Study Group.
    J Clin Psychiatry; 2007 Feb; 68(2):213-23. PubMed ID: 17335319
    [Abstract] [Full Text] [Related]

  • 10. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial.
    Shim JC, Shin JG, Kelly DL, Jung DU, Seo YS, Liu KH, Shon JH, Conley RR.
    Am J Psychiatry; 2007 Sep; 164(9):1404-10. PubMed ID: 17728426
    [Abstract] [Full Text] [Related]

  • 11. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study.
    Pigott TA, Carson WH, Saha AR, Torbeyns AF, Stock EG, Ingenito GG, Aripiprazole Study Group.
    J Clin Psychiatry; 2003 Sep; 64(9):1048-56. PubMed ID: 14628980
    [Abstract] [Full Text] [Related]

  • 12. A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia.
    Kane JM, Osuntokun O, Kryzhanovskaya LA, Xu W, Stauffer VL, Watson SB, Breier A.
    J Clin Psychiatry; 2009 Apr; 70(4):572-81. PubMed ID: 19323965
    [Abstract] [Full Text] [Related]

  • 13. Add-on of aripiprazole improves outcome in clozapine-resistant schizophrenia.
    De Risio A, Pancheri A, Simonetti G, Giannarelli D, Stefanutto L, Gentile B.
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun 01; 35(4):1112-6. PubMed ID: 21447367
    [Abstract] [Full Text] [Related]

  • 14. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial.
    Josiassen RC, Joseph A, Kohegyi E, Stokes S, Dadvand M, Paing WW, Shaughnessy RA.
    Am J Psychiatry; 2005 Jan 01; 162(1):130-6. PubMed ID: 15625211
    [Abstract] [Full Text] [Related]

  • 15. Aripiprazole augmentation in the management of residual symptoms in clozapine-treated outpatients with chronic schizophrenia: An open-label pilot study.
    Mitsonis CI, Dimopoulos NP, Mitropoulos PA, Kararizou EG, Katsa AN, Tsakiris FE, Katsanou MN.
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar 30; 31(2):373-7. PubMed ID: 17092620
    [Abstract] [Full Text] [Related]

  • 16. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo.
    Keck PE, Calabrese JR, McIntyre RS, McQuade RD, Carson WH, Eudicone JM, Carlson BX, Marcus RN, Sanchez R, Aripiprazole Study Group.
    J Clin Psychiatry; 2007 Oct 30; 68(10):1480-91. PubMed ID: 17960961
    [Abstract] [Full Text] [Related]

  • 17. Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia: a 12-month, randomized, naturalistic trial.
    Cipriani A, Accordini S, Nosè M, Purgato M, Girlanda F, Tansella M, Barbui C.
    J Clin Psychopharmacol; 2013 Aug 30; 33(4):533-7. PubMed ID: 23775051
    [Abstract] [Full Text] [Related]

  • 18. Aripiprazole effects in patients with acute schizophrenia experiencing higher or lower agitation: a post hoc analysis of 4 randomized, placebo-controlled clinical trials.
    Marder SR, West B, Lau GS, Pultz JA, Pikalov A, Marcus RN, Gutierrez-Esteinou R, Crandall DT.
    J Clin Psychiatry; 2007 May 30; 68(5):662-8. PubMed ID: 17503974
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects: a randomized, double-blind, active parallel-controlled, multicenter clinical trial.
    Li H, Luo J, Wang C, Xie S, Xu X, Wang X, Yu W, Gu N, Kane JM.
    Schizophr Res; 2014 Aug 30; 157(1-3):112-9. PubMed ID: 24994555
    [Abstract] [Full Text] [Related]

  • 20. Augmentation of clozapine with ziprasidone in refractory schizophrenia: a double-blind, placebo-controlled study.
    Muscatello MR, Pandolfo G, Micò U, Lamberti Castronuovo E, Abenavoli E, Scimeca G, Spina E, Zoccali R, Bruno A.
    J Clin Psychopharmacol; 2014 Feb 30; 34(1):129-33. PubMed ID: 24145221
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.